|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
affects localization increases expression |
EXP |
24-hydroxycholesterol affects the localization of ABCA1 protein 24-hydroxycholesterol results in increased expression of ABCA1 mRNA |
CTD |
PMID:16530456 |
|
NCBI chr 1:246,144,277...246,278,492
Ensembl chr 1:246,144,277...246,278,492
|
|
G |
APOA1 |
apolipoprotein A1 |
multiple interactions increases secretion |
EXP |
24-hydroxycholesterol promotes the reaction [APOA1 protein results in increased transport of Cholesterol] 24-hydroxycholesterol results in increased secretion of APOA1 protein |
CTD |
PMID:16530456 |
|
NCBI chr 9:44,216,481...44,218,360
Ensembl chr 9:44,216,392...44,218,713
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
increases metabolic processing |
EXP |
CYP7A1 protein results in increased metabolism of 24-hydroxycholesterol |
CTD |
PMID:11013305 |
|
NCBI chr 4:74,343,101...74,372,628
Ensembl chr 4:74,343,123...74,372,621
|
|
G |
LIPG |
lipase G, endothelial type |
decreases expression |
EXP |
24-hydroxycholesterol results in decreased expression of LIPG mRNA; 24-hydroxycholesterol results in decreased expression of LIPG protein |
CTD |
PMID:15953354 |
|
NCBI chr 1:99,081,940...99,110,671
Ensembl chr 1:99,081,938...99,110,874
|
|
G |
SCARB1 |
scavenger receptor class B member 1 |
affects localization |
EXP |
24-hydroxycholesterol affects the localization of SCARB1 protein |
CTD |
PMID:16530456 |
|
NCBI chr14:28,301,421...28,393,568
Ensembl chr14:28,301,294...28,393,568
|
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
increases metabolic processing |
EXP |
CYP7A1 protein results in increased metabolism of 27-hydroxycholesterol |
CTD |
PMID:10882719 |
|
NCBI chr 4:74,343,101...74,372,628
Ensembl chr 4:74,343,123...74,372,621
|
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
EXP |
Estradiol results in increased phosphorylation of ACACA protein |
CTD |
PMID:15967841 |
|
NCBI chr12:38,580,916...38,875,067
Ensembl chr12:38,581,457...38,824,712
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases secretion |
EXP |
Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; bisphenol A promotes the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Estradiol results in increased expression of and results in increased secretion of ADIPOQ protein; halowax 1051 inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Hexachlorobenzene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol] |
CTD |
PMID:28284726 |
|
NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,685...124,646,646
|
|
G |
ADIPOR1 |
adiponectin receptor 1 |
increases expression |
EXP |
Estradiol results in increased expression of ADIPOR1 protein |
CTD |
PMID:28284726 |
|
NCBI chr10:24,907,491...24,923,540
Ensembl chr10:24,907,491...24,915,686
|
|
G |
ADIPOR2 |
adiponectin receptor 2 |
increases expression |
EXP |
Estradiol results in increased expression of ADIPOR2 protein |
CTD |
PMID:28284726 |
|
NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
EXP |
Estradiol results in increased phosphorylation of AKT1 protein |
CTD |
PMID:17348974 |
|
|
|
G |
CD40 |
CD40 molecule |
affects expression |
EXP |
Estradiol affects the expression of CD40 protein |
CTD |
PMID:15964915 |
|
NCBI chr17:48,286,116...48,298,188
Ensembl chr17:48,286,029...48,298,528
|
|
G |
CD40LG |
CD40 ligand |
affects expression |
EXP |
Estradiol affects the expression of CD40LG protein |
CTD |
PMID:15964915 |
|
NCBI chr X:111,778,666...111,788,901
Ensembl chr X:111,778,493...111,789,709
|
|
G |
ESR1 |
estrogen receptor 1 |
decreases expression affects expression |
EXP |
Estradiol results in decreased expression of ESR1 protein; Estradiol results in decreased expression of ESR1 protein alternative form Estradiol affects the expression of ESR1 protein |
CTD |
PMID:15653758 PMID:16431846 PMID:16680078 PMID:17348974 |
|
NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
|
|
G |
ESR2 |
estrogen receptor 2 |
affects expression |
EXP |
Estradiol affects the expression of ESR2 protein |
CTD |
PMID:15653758 PMID:16680078 |
|
NCBI chr 1:193,823,666...193,907,330
Ensembl chr 1:193,829,560...193,906,565
|
|
G |
F3 |
coagulation factor III, tissue factor |
affects expression |
EXP |
Estradiol affects the expression of F3 mRNA; Estradiol affects the expression of F3 protein |
CTD |
PMID:15964915 |
|
NCBI chr 4:122,827,018...122,837,673
Ensembl chr 4:122,826,644...122,837,666
|
|
G |
FGF7 |
fibroblast growth factor 7 |
increases expression |
EXP |
Estradiol results in increased expression of FGF7 mRNA |
CTD |
PMID:15271478 |
|
NCBI chr 1:122,215,878...122,278,705
Ensembl chr 1:122,215,882...122,277,750
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions increases chemical synthesis |
EXP |
[FSHB protein co-treated with Androstenedione] results in increased chemical synthesis of and results in increased secretion of Estradiol; [FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol; bisphenol AF inhibits the reaction [[FSHB protein co-treated with Androstenedione] results in increased chemical synthesis of and results in increased secretion of Estradiol]; bisphenol S inhibits the reaction [[FSHB protein co-treated with Androstenedione] results in increased chemical synthesis of and results in increased secretion of Estradiol]; deoxynivalenol affects the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol]; lead acetate inhibits the reaction [FSHB protein results in increased chemical synthesis of Estradiol] |
CTD |
PMID:17656051 PMID:29273543 PMID:34019995 |
|
NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274
|
|
G |
HOXA10 |
homeobox A10 |
increases expression multiple interactions |
EXP |
Estradiol results in increased expression of HOXA10 mRNA Estradiol promotes the reaction [Progesterone results in increased expression of HOXA10 mRNA]; Fulvestrant inhibits the reaction [Estradiol results in increased expression of HOXA10 mRNA] |
CTD |
PMID:21705055 |
|
NCBI chr18:45,393,525...45,403,259
Ensembl chr18:45,393,885...45,403,257
|
|
G |
IGF1 |
insulin like growth factor 1 |
multiple interactions increases abundance |
EXP |
[FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol; deoxynivalenol affects the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol]; deoxynivalenol affects the reaction [IGF1 protein results in increased abundance of Estradiol]; Zearalenone affects the reaction [IGF1 protein results in increased abundance of Estradiol] |
CTD |
PMID:17656051 |
|
NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,033
|
|
G |
LEP |
leptin |
increases secretion increases expression |
EXP |
Estradiol results in increased secretion of LEP protein Estradiol results in increased expression of LEP mRNA |
CTD |
PMID:23153703 |
|
NCBI chr18:20,106,867...20,124,071
Ensembl chr18:20,106,868...20,123,323
|
|
G |
LHB |
luteinizing hormone subunit beta |
multiple interactions increases secretion |
EXP |
Biological Products inhibits the reaction [LHB protein results in increased secretion of Estradiol]; Cod Liver Oil inhibits the reaction [LHB protein results in increased secretion of Estradiol]; Industrial Waste inhibits the reaction [LHB protein results in increased secretion of Estradiol] |
CTD |
PMID:26055946 |
|
NCBI chr 6:54,263,574...54,269,286
Ensembl chr 6:54,263,576...54,271,086
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
affects secretion |
EXP |
Estradiol affects the secretion of MMP2 protein |
CTD |
PMID:15653758 |
|
NCBI chr 6:30,059,247...30,087,031
Ensembl chr 6:30,058,595...30,086,982
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions affects expression increases phosphorylation decreases expression |
EXP |
Estradiol results in increased phosphorylation of and results in increased activity of NOS3 protein; Fulvestrant inhibits the reaction [Estradiol results in increased phosphorylation of NOS3 protein] Estradiol affects the expression of NOS3 mRNA Estradiol results in decreased expression of NOS3 mRNA |
CTD |
PMID:15653758 PMID:15967841 PMID:16680078 PMID:17618301 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
G |
PDGFB |
platelet derived growth factor subunit B |
multiple interactions |
EXP |
Estradiol affects the secretion of [PDGFB protein binds to PDGFB protein] |
CTD |
PMID:15653758 |
|
Ensembl chr 5:8,986,462...9,007,435
|
|
G |
PGR |
progesterone receptor |
increases expression |
EXP |
Estradiol results in increased expression of PGR mRNA |
CTD |
PMID:16431846 |
|
NCBI chr 9:32,035,684...32,129,776
Ensembl chr 9:32,035,684...32,129,221
|
|
G |
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
EXP |
Estradiol results in increased phosphorylation of and results in increased activity of PRKAA1 protein |
CTD |
PMID:15967841 |
|
NCBI chr16:25,745,902...25,783,524
Ensembl chr16:25,745,324...25,783,707
|
|
G |
PRLR |
prolactin receptor |
increases expression |
EXP |
Estradiol results in increased expression of PRLR protein alternative form |
CTD |
PMID:18492821 |
|
NCBI chr16:20,637,568...20,655,881
Ensembl chr16:20,618,875...20,810,140
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP |
Estradiol results in increased expression of PTGS2 mRNA Fulvestrant inhibits the reaction [Estradiol results in increased expression of PTGS2 mRNA] |
CTD |
PMID:21705055 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
decreases expression |
EXP |
Estradiol results in decreased expression of SPP1 protein |
CTD |
PMID:15713688 |
|
NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
|
|
G |
TNFRSF11B |
TNF receptor superfamily member 11b |
increases expression |
EXP |
Estradiol results in increased expression of TNFRSF11B protein |
CTD |
PMID:15713688 |
|
NCBI chr 4:19,850,212...19,879,132
Ensembl chr 4:19,850,350...19,879,125
|
|
|
G |
FGF7 |
fibroblast growth factor 7 |
affects expression |
EXP |
estradiol 3-benzoate affects the expression of FGF7 mRNA |
CTD |
PMID:15976484 |
|
NCBI chr 1:122,215,878...122,278,705
Ensembl chr 1:122,215,882...122,277,750
|
|
G |
FGFR2 |
fibroblast growth factor receptor 2 |
decreases expression multiple interactions |
EXP |
estradiol 3-benzoate results in decreased expression of FGFR2 mRNA alternative form [Progesterone co-treated with estradiol 3-benzoate] results in decreased expression of FGFR2 mRNA alternative form |
CTD |
PMID:15976484 |
|
NCBI chr14:131,183,095...131,285,001
Ensembl chr14:131,181,713...131,289,425
|
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
increases metabolic processing |
EXP |
CYP7A1 protein results in increased metabolism of 20-hydroxycholesterol |
CTD |
PMID:10882719 |
|
NCBI chr 4:74,343,101...74,372,628
Ensembl chr 4:74,343,123...74,372,621
|
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
increases metabolic processing |
EXP |
CYP7A1 protein results in increased metabolism of 25-hydroxycholesterol |
CTD |
PMID:10882719 |
|
NCBI chr 4:74,343,101...74,372,628
Ensembl chr 4:74,343,123...74,372,621
|
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
increases metabolic processing |
EXP |
CYP7A1 protein results in increased metabolism of 27-hydroxycholesterol |
CTD |
PMID:10882719 |
|
NCBI chr 4:74,343,101...74,372,628
Ensembl chr 4:74,343,123...74,372,621
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of BAX mRNA] |
CTD |
PMID:28803810 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,147
|
|
G |
BECN1 |
beclin 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of BECN1 mRNA]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of BECN1 protein]]; 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of BECN1 protein] |
CTD |
PMID:28803810 PMID:34811946 |
|
NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein] |
CTD |
PMID:28803810 PMID:30287338 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP8 protein] |
CTD |
PMID:28803810 |
|
NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the activity of CAT protein] |
CTD |
PMID:34811946 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of CYCS mRNA] |
CTD |
PMID:28803810 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
DCTN4 |
dynactin subunit 4 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of DCTN4 mRNA] |
CTD |
PMID:34811946 |
|
NCBI chr 2:151,681,001...151,713,923
Ensembl chr 2:151,681,003...151,783,746
|
|
G |
FGD4 |
FYVE, RhoGEF and PH domain containing 4 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L protein]] |
CTD |
PMID:34811946 |
|
NCBI chr 5:41,571,054...41,636,058
Ensembl chr 5:41,570,282...41,636,028
|
|
G |
FIS1 |
fission, mitochondrial 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of FIS1 mRNA]] |
CTD |
PMID:34811946 |
|
NCBI chr 3:8,938,250...8,942,102
Ensembl chr 3:8,937,453...8,946,955
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of GPX1 mRNA] |
CTD |
PMID:34811946 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
LAMP2 |
lysosomal associated membrane protein 2 |
decreases expression |
EXP |
3-methyladenine results in decreased expression of LAMP2 protein |
CTD |
PMID:36754226 |
|
NCBI chr X:98,586,718...98,623,939
Ensembl chr X:98,581,992...98,623,940
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions decreases lipidation |
EXP |
3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the lipidation of MAP1LC3B protein]]; Benzo(a)pyrene promotes the reaction [3-methyladenine results in decreased lipidation of MAP1LC3B protein] |
CTD |
PMID:34811946 PMID:36754226 |
|
NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of MKI67 protein]] |
CTD |
PMID:34811946 |
|
NCBI chr14:137,266,622...137,296,312
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the activity of CAT protein]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of BECN1 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of DCTN4 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of GPX1 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of SOD1 mRNA]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of MKI67 protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of OPA1 mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of TOMM20 protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of FIS1 mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of PARP1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of BECN1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of SQSTM1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the lipidation of MAP1LC3B protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the phosphorylation of TP53 protein]] |
CTD |
PMID:34811946 |
|
NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109
|
|
G |
OPA1 |
OPA1 mitochondrial dynamin like GTPase |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of OPA1 mRNA]] |
CTD |
PMID:34811946 |
|
NCBI chr13:130,624,771...130,718,345
Ensembl chr13:130,624,796...130,719,083
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of PARP1 protein]]; 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein] |
CTD |
PMID:30287338 PMID:34811946 |
|
NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,160...14,241,196
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of SOD1 mRNA] |
CTD |
PMID:34811946 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of SQSTM1 protein]]; 3-methyladenine inhibits the reaction [Zinc Sulfate results in decreased expression of SQSTM1 protein] |
CTD |
PMID:28803810 PMID:34811946 |
|
NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938
|
|
G |
TOMM20 |
translocase of outer mitochondrial membrane 20 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of TOMM20 protein]] |
CTD |
PMID:34811946 |
|
NCBI chr14:56,113,087...56,127,686
Ensembl chr14:56,113,192...56,127,677
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the phosphorylation of TP53 protein]] |
CTD |
PMID:34811946 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|
|
G |
TPO |
thyroid peroxidase |
decreases activity |
EXP |
Propylthiouracil results in decreased activity of TPO protein |
CTD |
PMID:23959146 |
|
NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208
|
|
|
G |
CYP3A29 |
cytochrome P450 family 3 subfamily A member 29 |
increases chemical synthesis multiple interactions |
EXP |
CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone Ketoconazole inhibits the reaction [CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Troleandomycin inhibits the reaction [CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone] |
CTD |
PMID:20863320 |
|
NCBI chr 3:6,738,502...6,778,121
Ensembl chr 3:6,738,486...6,778,944
|
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions |
EXP |
7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein] |
CTD |
PMID:11042205 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Aspirin inhibits the reaction [Hydrogen Peroxide results in increased expression of HSPA5 protein] |
CTD |
PMID:20665602 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
PLA2G1B |
phospholipase A2 group IB |
multiple interactions |
EXP |
Aspirin promotes the reaction [PLA2G1B protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:10706128 |
|
NCBI chr14:40,314,520...40,322,315
Ensembl chr14:40,314,520...40,322,315
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Aspirin promotes the reaction [PLA2G1B protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:10706128 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
|
G |
MYL9 |
myosin light chain 9 |
decreases phosphorylation multiple interactions |
EXP |
Adenosine results in decreased phosphorylation of MYL9 protein 8-phenyltheophylline inhibits the reaction [Adenosine results in decreased phosphorylation of MYL9 protein] |
CTD |
PMID:10942722 |
|
NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293
|
|
|
G |
CYP2C49 |
cytochrome P450 2C49 |
decreases response to substance |
EXP |
CYP2C49 protein results in decreased susceptibility to alachlor |
CTD |
PMID:16315095 |
|
NCBI chr14:106,571,803...106,612,082
Ensembl chr14:106,285,173...106,612,455
|
|
|
G |
PDIA3 |
protein disulfide isomerase family A member 3 |
increases hydrolysis |
EXP |
PDIA3 protein results in increased hydrolysis of retinol palmitate |
CTD |
PMID:16798117 |
|
NCBI chr 1:127,786,174...127,814,096
Ensembl chr 1:127,785,772...127,814,196
|
|
|
G |
INS |
insulin |
increases uptake multiple interactions |
EXP |
INS protein results in increased uptake of 2-(methylamino)isobutyric acid Dimercaprol inhibits the reaction [oxophenylarsine inhibits the reaction [INS protein results in increased uptake of 2-(methylamino)isobutyric acid]]; oxophenylarsine inhibits the reaction [INS protein results in increased uptake of 2-(methylamino)isobutyric acid] |
CTD |
PMID:1928324 |
|
NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
|
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
[FSHB protein co-treated with Androstenedione] results in increased chemical synthesis of and results in increased secretion of Estradiol; bisphenol AF inhibits the reaction [[FSHB protein co-treated with Androstenedione] results in increased chemical synthesis of and results in increased secretion of Estradiol]; bisphenol S inhibits the reaction [[FSHB protein co-treated with Androstenedione] results in increased chemical synthesis of and results in increased secretion of Estradiol] |
CTD |
PMID:34019995 |
|
NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274
|
|
G |
HSD17B1 |
hydroxysteroid 17-beta dehydrogenase 1 |
multiple interactions |
EXP |
[2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Androstenedione] results in increased activity of HSD17B1 protein |
CTD |
PMID:16151981 |
|
NCBI chr12:20,269,468...20,271,349
Ensembl chr12:20,269,056...20,271,548
|
|
G |
INS |
insulin |
multiple interactions |
EXP |
9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione]; [LHB protein co-treated with INS protein] results in increased abundance of Androstenedione; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione] |
CTD |
PMID:11889176 |
|
NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
|
|
G |
LHB |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione]; [LHB protein co-treated with INS protein] results in increased abundance of Androstenedione; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione] |
CTD |
PMID:11889176 |
|
NCBI chr 6:54,263,574...54,269,286
Ensembl chr 6:54,263,576...54,271,086
|
|
|
G |
ENPEP |
glutamyl aminopeptidase |
multiple interactions increases hydrolysis |
EXP |
1,10-phenanthroline inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; amastatin inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; Calcium Chloride promotes the reaction [ENPEP protein results in increased hydrolysis of Aspartame] |
CTD |
PMID:8141778 |
|
NCBI chr 8:111,765,839...111,858,349
Ensembl chr 8:111,748,514...111,858,510
|
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
increases expression multiple interactions |
EXP |
Adenosine Triphosphate results in increased expression of BCL2 protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of BCL2 protein] |
CTD |
PMID:17997382 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP8 |
caspase 8 |
increases activity multiple interactions |
EXP |
Adenosine Triphosphate results in increased activity of CASP8 protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased activity of CASP8 protein] |
CTD |
PMID:17997382 |
|
NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
|
|
G |
CYCS |
cytochrome c, somatic |
affects localization multiple interactions |
EXP |
Adenosine Triphosphate affects the localization of CYCS protein [Calcium co-treated with Phosphates co-treated with Adenosine Triphosphate] affects the localization of CYCS protein; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate affects the localization of CYCS protein] |
CTD |
PMID:16489745 PMID:17997382 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
MYL9 |
myosin light chain 9 |
decreases phosphorylation multiple interactions |
EXP |
Adenosine Triphosphate results in decreased phosphorylation of MYL9 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]]; Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:10942722 |
|
NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293
|
|
G |
TNF |
tumor necrosis factor |
increases expression multiple interactions |
EXP |
Adenosine Triphosphate results in increased expression of TNF protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of TNF protein] |
CTD |
PMID:17997382 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,415
|
|
|
G |
CYP2B6B |
cytochrome P450 family 2 subfamily B member 6B |
decreases response to substance |
EXP |
CYP2B6B protein results in decreased susceptibility to chlortoluron |
CTD |
PMID:16315095 |
|
NCBI chr 6:49,158,175...49,173,872
Ensembl chr 6:49,110,812...49,178,334
|
|
G |
CYP2C49 |
cytochrome P450 2C49 |
decreases response to substance |
EXP |
CYP2C49 protein results in decreased susceptibility to chlortoluron |
CTD |
PMID:16315095 |
|
NCBI chr14:106,571,803...106,612,082
Ensembl chr14:106,285,173...106,612,455
|
|
|
G |
APOA1 |
apolipoprotein A1 |
increases transport multiple interactions |
EXP |
APOA1 protein results in increased transport of Cholesterol 24-hydroxycholesterol promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Fenofibrate inhibits the reaction [APOA1 protein results in increased transport of Cholesterol]; Fenofibrate promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Pioglitazone promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; T0901317 promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Troglitazone promotes the reaction [APOA1 protein results in increased transport of Cholesterol] |
CTD |
PMID:16530456 |
|
NCBI chr 9:44,216,481...44,218,360
Ensembl chr 9:44,216,392...44,218,713
|
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein |
CTD |
PMID:29129240 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844
|
|
G |
DNMT3A |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA |
CTD |
PMID:29129240 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GYS1 |
glycogen synthase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with bisphenol A] results in increased methylation of GYS1 promoter; [Betaine co-treated with Choline co-treated with Folic Acid] results in decreased expression of GYS1 mRNA; [Betaine co-treated with Choline co-treated with Folic Acid] results in increased methylation of GYS1 promoter |
CTD |
PMID:29065941 |
|
NCBI chr 6:54,234,600...54,250,211
Ensembl chr 6:54,233,050...54,250,261
|
|
G |
LDHA |
lactate dehydrogenase A |
multiple interactions |
EXP |
[bisphenol A co-treated with Choline co-treated with Folic Acid co-treated with Betaine] results in decreased methylation of LDHA promoter |
CTD |
PMID:29065941 |
|
NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715
|
|
G |
MTHFR |
methylenetetrahydrofolate reductase |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of MTHFR mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 6:71,863,637...71,882,118
Ensembl chr 6:71,863,637...71,881,820
|
|
G |
SI |
sucrase-isomaltase |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SI mRNA |
CTD |
PMID:28445388 |
|
NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478
|
|
G |
SLC15A1 |
solute carrier family 15 member 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933
|
|
G |
SLC5A1 |
solute carrier family 5 member 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA |
CTD |
PMID:29129240 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
|
G |
ACO1 |
aconitase 1 |
increases expression |
EXP |
Clofibrate results in increased expression of ACO1 mRNA |
CTD |
PMID:17363680 |
|
NCBI chr10:33,937,833...34,001,895
Ensembl chr10:33,937,833...34,001,900
|
|
G |
ACOX1 |
acyl-CoA oxidase 1 |
increases expression |
EXP |
Clofibrate results in increased expression of ACOX1 mRNA |
CTD |
PMID:16896063 PMID:17437637 |
|
NCBI chr12:5,450,913...5,479,550
Ensembl chr12:5,439,361...5,479,546
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
EXP |
Clofibrate inhibits the reaction [AGT protein modified form results in increased expression of EDN1 protein] |
CTD |
PMID:17105827 |
|
NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
|
|
G |
ALB |
albumin |
decreases expression |
EXP |
Clofibrate results in decreased expression of ALB mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 8:69,643,427...69,663,152
Ensembl chr 8:69,531,487...69,721,696
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Clofibrate results in increased expression of BAX mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,147
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:17437637 |
|
NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694
|
|
G |
CAT |
catalase |
increases expression |
EXP |
Clofibrate results in increased expression of CAT mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
increases expression |
EXP |
Clofibrate results in increased expression of CPT1A mRNA |
CTD |
PMID:16896063 PMID:17363680 |
|
NCBI chr 2:4,250,642...4,293,914
Ensembl chr 2:4,233,099...4,293,911
|
|
G |
CTSB |
cathepsin B |
increases expression |
EXP |
Clofibrate results in increased expression of CTSB mRNA |
CTD |
PMID:16896063 |
|
NCBI chr14:15,014,139...15,035,081
Ensembl chr14:15,011,711...15,033,877
|
|
G |
DIO2 |
iodothyronine deiodinase 2 |
decreases expression |
EXP |
Clofibrate results in decreased expression of DIO2 mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 7:103,096,414...103,110,749
Ensembl chr 7:103,096,433...103,323,258
|
|
G |
EDN1 |
endothelin 1 |
decreases expression multiple interactions |
EXP |
Clofibrate results in decreased expression of EDN1 protein Clofibrate inhibits the reaction [AGT protein modified form results in increased expression of EDN1 protein]; Clofibrate inhibits the reaction [KNG1 protein modified form results in increased expression of EDN1 protein]; Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EDN1 protein]; Nitric Oxide deficiency inhibits the reaction [Clofibrate results in decreased expression of EDN1 protein] |
CTD |
PMID:17105827 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
G |
FABP1 |
fatty acid binding protein 1 |
increases expression |
EXP |
Clofibrate results in increased expression of FABP1 mRNA |
CTD |
PMID:17363680 |
|
NCBI chr 3:57,850,511...57,854,966
Ensembl chr 3:57,850,499...57,854,956
|
|
G |
GPX1 |
glutathione peroxidase 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of GPX1 mRNA |
CTD |
PMID:17437637 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
HMGCS2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
EXP |
Clofibrate results in increased expression of HMGCS2 mRNA |
CTD |
PMID:17363680 |
|
NCBI chr 4:101,420,941...101,440,302
Ensembl chr 4:101,420,872...101,438,126
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Clofibrate results in increased expression of JUN mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 6:153,686,425...153,687,635
Ensembl chr 6:153,685,682...153,687,636
|
|
G |
KNG1 |
kininogen 1 |
multiple interactions |
EXP |
Clofibrate inhibits the reaction [KNG1 protein modified form results in increased expression of EDN1 protein] |
CTD |
PMID:17105827 |
|
NCBI chr13:124,521,276...124,557,384
Ensembl chr13:124,521,340...124,557,958
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
EXP |
Clofibrate results in increased expression of MYC mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 4:12,455,141...12,460,360
Ensembl chr 4:12,455,122...12,461,078
|
|
G |
NOS3 |
nitric oxide synthase 3 |
increases expression multiple interactions |
EXP |
Clofibrate results in increased expression of NOS3 protein calphostin C inhibits the reaction [Clofibrate results in increased expression of NOS3 protein] |
CTD |
PMID:17105827 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
EXP |
Clofibrate results in increased expression of PPARA; Clofibrate results in increased expression of PPARA protein calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA protein]; calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA]; Tetradecanoylphorbol Acetate inhibits the reaction [Clofibrate results in increased expression of PPARA] |
CTD |
PMID:17105827 PMID:20568414 |
|
NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239
|
|
G |
SCD |
stearoyl-CoA desaturase |
increases expression |
EXP |
Clofibrate results in increased expression of SCD mRNA |
CTD |
PMID:17363680 |
|
NCBI chr14:111,461,560...111,478,033
Ensembl chr14:111,461,569...111,478,020
|
|
G |
SLC5A5 |
solute carrier family 5 member 5 |
increases expression |
EXP |
Clofibrate results in increased expression of SLC5A5 mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 2:59,869,157...59,885,086
Ensembl chr 2:59,869,155...59,885,266
|
|
G |
SOD1 |
superoxide dismutase 1 |
increases expression |
EXP |
Clofibrate results in increased expression of SOD1 mRNA |
CTD |
PMID:17437637 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
THRA |
thyroid hormone receptor alpha |
decreases expression |
EXP |
Clofibrate results in decreased expression of THRA mRNA |
CTD |
PMID:16896063 |
|
NCBI chr12:22,270,506...22,296,684
Ensembl chr12:22,270,062...22,296,618
|
|
G |
TNF |
tumor necrosis factor |
decreases expression |
EXP |
Clofibrate results in decreased expression of TNF mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,415
|
|
G |
TPO |
thyroid peroxidase |
increases expression |
EXP |
Clofibrate results in increased expression of TPO mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208
|
|
G |
TSHR |
thyroid stimulating hormone receptor |
increases expression |
EXP |
Clofibrate results in increased expression of TSHR mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 7:103,768,260...103,925,777
Ensembl chr 7:103,768,296...103,925,922
|
|
G |
TTR |
transthyretin |
decreases expression |
EXP |
Clofibrate results in decreased expression of TTR mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 6:115,496,338...115,503,974
Ensembl chr 6:115,496,326...115,503,977
|
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Carvedilol results in decreased expression of EDN1 protein] |
CTD |
PMID:18840580 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
CAT protein inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; CAT protein results in decreased activity of [Hypoxanthine co-treated with XDH protein] |
CTD |
PMID:21984542 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
XDH |
xanthine dehydrogenase |
multiple interactions |
EXP |
[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide; [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Hydrogen Peroxide; [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Superoxides; CAT protein inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; CAT protein results in decreased activity of [Hypoxanthine co-treated with XDH protein]; tempol inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; tempol results in decreased activity of [Hypoxanthine co-treated with XDH protein] |
CTD |
PMID:21984542 |
|
NCBI chr 3:107,987,060...108,052,043
Ensembl chr 3:107,987,126...108,053,169
|
|
|
G |
AGT |
angiotensinogen |
affects activity |
EXP |
Indomethacin affects the activity of AGT protein |
CTD |
PMID:21127344 |
|
NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
EXP |
Indomethacin results in increased expression of DDIT3 mRNA |
CTD |
PMID:18799549 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Indomethacin results in increased expression of HSPA5 mRNA |
CTD |
PMID:18799549 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
leptomycin B inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA] |
CTD |
PMID:34520801 |
|
NCBI chr17:15,750,487...15,762,982
Ensembl chr17:15,749,835...15,761,195
|
|
|
G |
ANXA5 |
annexin A5 |
multiple interactions increases activity |
EXP |
Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]; TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]] |
CTD |
PMID:10617950 |
|
NCBI chr 8:102,387,833...102,420,868
Ensembl chr 8:102,388,103...102,425,750
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases activity |
EXP |
Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]; Zinc Acetate inhibits the reaction [Linoleic Acid results in increased activity of CASP3 protein]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; Zinc Acetate promotes the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]] |
CTD |
PMID:10617950 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
IL6 |
interleukin 6 |
increases expression multiple interactions |
EXP |
Linoleic Acid results in increased expression of IL6 mRNA; Linoleic Acid results in increased expression of IL6 protein 2,4-thiazolidinedione inhibits the reaction [Linoleic Acid results in increased expression of IL6 protein]; PPARG protein promotes the reaction [Linoleic Acid results in increased expression of IL6 protein]; Quercetin inhibits the reaction [Linoleic Acid results in increased expression of IL6 mRNA] |
CTD |
PMID:14519784 PMID:15051824 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions increases activity |
EXP |
PPARG protein promotes the reaction [Linoleic Acid results in increased activity of RELA protein]; PPARG protein promotes the reaction [Linoleic Acid results in increased expression of IL6 protein]; Quercetin inhibits the reaction [Linoleic Acid results in increased activity of PPARG protein]; Vitamin E inhibits the reaction [Linoleic Acid results in increased activity of PPARG protein] |
CTD |
PMID:14519784 PMID:15051824 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP |
Linoleic Acid results in increased expression of PTGS2 mRNA Linoleic Acid promotes the reaction [[Polychlorinated Biphenyls results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Linoleic Acid promotes the reaction [Polychlorinated Biphenyls results in increased expression of PTGS2 mRNA]; Linoleic Acid promotes the reaction [Polychlorinated Biphenyls results in increased expression of PTGS2 protein]; Polychlorinated Biphenyls promotes the reaction [[Linoleic Acid results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; prolinedithiocarbamate inhibits the reaction [[Linoleic Acid co-treated with Polychlorinated Biphenyls] results in increased expression of PTGS2 mRNA]; prolinedithiocarbamate inhibits the reaction [Linoleic Acid results in increased expression of PTGS2 mRNA] |
CTD |
PMID:18155686 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases activity |
EXP |
2,4-thiazolidinedione inhibits the reaction [Linoleic Acid results in increased activity of RELA protein]; PPARG protein promotes the reaction [Linoleic Acid results in increased activity of RELA protein] |
CTD |
PMID:14519784 |
|
NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]; Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]; TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]]; Zinc Acetate promotes the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]] |
CTD |
PMID:10617950 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,415
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
increases expression multiple interactions |
EXP |
Linoleic Acid results in increased expression of VCAM1 mRNA [Linoleic Acid co-treated with Polychlorinated Biphenyls] results in increased expression of VCAM1 protein; Linoleic Acid promotes the reaction [Polychlorinated Biphenyls results in increased expression of VCAM1 mRNA]; prolinedithiocarbamate inhibits the reaction [Linoleic Acid results in increased expression of VCAM1 mRNA]; Quercetin inhibits the reaction [Linoleic Acid results in increased expression of VCAM1 mRNA] |
CTD |
PMID:15051824 PMID:18155686 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; Acetylcysteine inhibits the reaction [Cadmium results in increased expression of BAX protein] |
CTD |
PMID:19135140 PMID:33905761 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,147
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
EXP |
[Acetylcysteine co-treated with fumonisin B1 co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with fumonisin B1] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone] results in increased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [Cadmium results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]] |
CTD |
PMID:19135140 PMID:29109043 PMID:33905761 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
BMP15 |
bone morphogenetic protein 15 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of BMP15 mRNA] |
CTD |
PMID:26386189 |
|
NCBI chr X:44,613,122...44,620,575
Ensembl chr X:44,613,122...44,620,575
|
|
G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein] |
CTD |
PMID:36281498 |
|
NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
[Acetylcysteine co-treated with Zearalenone] results in decreased expression of CASP3 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [Cadmium results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]] |
CTD |
PMID:17383151 PMID:19135140 PMID:29109043 PMID:33905761 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; Acetylcysteine inhibits the reaction [Cadmium results in increased activity of CASP9 protein] |
CTD |
PMID:19135140 PMID:33905761 |
|
NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA] |
CTD |
PMID:19265715 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]] |
CTD |
PMID:29109043 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of DDIT3 mRNA] |
CTD |
PMID:18086661 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of FOS mRNA] |
CTD |
PMID:18086661 |
|
NCBI chr 7:98,449,508...98,451,971
Ensembl chr 7:98,449,349...98,455,554
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GPX4 |
glutathione peroxidase 4 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931
|
|
G |
GSDMD |
gasdermin D |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein] |
CTD |
PMID:36281498 |
|
NCBI chr 4:995,753...1,001,964
Ensembl chr 4:995,763...1,000,271
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]] |
CTD |
PMID:29109043 |
|
NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,984
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of HSP90B1 mRNA] |
CTD |
PMID:18086661 |
|
NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA5 mRNA] |
CTD |
PMID:18086661 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein] |
CTD |
PMID:36281498 |
|
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:17383151 |
|
NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:17383151 |
|
NCBI chr 2:78,338,466...78,399,108
Ensembl chr 2:78,338,376...78,399,100
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cisplatin results in increased expression of MYC] |
CTD |
PMID:12712633 |
|
NCBI chr 4:12,455,141...12,460,360
Ensembl chr 4:12,455,122...12,461,078
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein] |
CTD |
PMID:24512358 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein] |
CTD |
PMID:36281498 |
|
NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of INOS mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PTGS2 mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
PTX3 |
pentraxin 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of PTX3 mRNA] |
CTD |
PMID:26386189 |
|
NCBI chr13:97,273,594...97,279,570
Ensembl chr13:97,273,594...97,279,569
|
|
G |
PYCARD |
PYD and CARD domain containing |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein] |
CTD |
PMID:36281498 |
|
NCBI chr 3:17,305,921...17,307,521
Ensembl chr 3:17,306,099...17,307,786
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Glyphosate results in decreased expression of SQSTM1 protein] |
CTD |
PMID:35388968 |
|
NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938
|
|
G |
TNFAIP6 |
TNF alpha induced protein 6 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of TNFAIP6 mRNA] |
CTD |
PMID:26386189 |
|
NCBI chr15:862,013...881,352
Ensembl chr15:862,015...881,461
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]]; Acetylcysteine promotes the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]] |
CTD |
PMID:29109043 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|
G |
ZP3 |
zona pellucida glycoprotein 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of ZP3 mRNA] |
CTD |
PMID:26386189 |
|
NCBI chr 3:9,934,760...9,944,924
Ensembl chr 3:9,934,760...9,944,941
|
|
|
G |
SLC22A5 |
solute carrier family 22 member 5 |
increases uptake |
EXP |
SLC22A5 protein results in increased uptake of Acetylcarnitine |
CTD |
PMID:16826461 |
|
NCBI chr 2:134,660,741...134,847,575
Ensembl chr 2:134,660,808...134,686,219
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
EXP |
ochratoxin A results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:30287338 |
|
|
|
G |
ANXA5 |
annexin A5 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of ANXA5 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 8:102,387,833...102,420,868
Ensembl chr 8:102,388,103...102,425,750
|
|
G |
APAF1 |
apoptotic peptidase activating factor 1 |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of APAF1 mRNA; ochratoxin A results in increased expression of APAF1 protein fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 protein] |
CTD |
PMID:36397609 |
|
NCBI chr 5:85,166,616...85,258,751
Ensembl chr 5:85,166,628...85,258,364
|
|
G |
ATG5 |
autophagy related 5 |
multiple interactions increases expression |
EXP |
ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein] ochratoxin A results in increased expression of ATG5 protein |
CTD |
PMID:28699257 PMID:30287338 |
|
NCBI chr 1:72,343,950...72,520,402
Ensembl chr 1:72,270,799...72,520,396
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA] ochratoxin A results in increased expression of BAX mRNA; ochratoxin A results in increased expression of BAX protein |
CTD |
PMID:33905761 PMID:36397609 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,147
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions decreases expression affects expression |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA] ochratoxin A results in decreased expression of BCL2 mRNA; ochratoxin A results in decreased expression of BCL2 protein |
CTD |
PMID:28528741 PMID:29080797 PMID:33905761 PMID:36397609 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
BECN1 |
beclin 1 |
multiple interactions increases expression |
EXP |
BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein] ochratoxin A results in increased expression of BECN1 protein |
CTD |
PMID:30287338 |
|
NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373
|
|
G |
BRCA1 |
BRCA1 DNA repair associated |
increases expression |
EXP |
ochratoxin A results in increased expression of BRCA1 protein |
CTD |
PMID:32454083 |
|
NCBI chr12:19,788,087...19,854,515
Ensembl chr12:19,786,020...19,854,668
|
|
G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein]; ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein; Taurine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein] |
CTD |
PMID:36281498 |
|
NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases expression increases cleavage |
EXP |
3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein] ochratoxin A results in increased expression of CASP3 mRNA; ochratoxin A results in increased expression of CASP3 protein; ochratoxin A results in increased expression of CASP3 protein modified form |
CTD |
PMID:30287338 PMID:33905761 PMID:36397609 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP9 |
caspase 9 |
multiple interactions increases expression |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein] ochratoxin A results in increased expression of CASP9 mRNA; ochratoxin A results in increased expression of CASP9 protein; ochratoxin A results in increased expression of CASP9 protein modified form |
CTD |
PMID:33905761 PMID:36397609 |
|
NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
|
|
G |
CAT |
catalase |
decreases expression multiple interactions |
EXP |
ochratoxin A results in decreased expression of CAT mRNA; ochratoxin A results in decreased expression of CAT protein Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA] |
CTD |
PMID:18547704 PMID:36281498 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CRYAB |
crystallin alpha B |
increases expression |
EXP |
ochratoxin A results in increased expression of CRYAB mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 9:39,638,505...39,643,530
Ensembl chr 9:39,638,506...39,643,530
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions increases expression |
EXP |
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CYCS mRNA] |
CTD |
PMID:36397609 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
CYP2A19 |
cytochrome P450 family 2 subfamily A member 19 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of CYP2A6 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 6:49,056,579...49,064,111
Ensembl chr 6:49,056,578...49,064,107
|
|
G |
DAD1 |
defender against cell death 1 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of DAD1 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 7:76,432,040...76,457,403
Ensembl chr 7:76,432,051...76,457,192
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of DNMT1 mRNA; ochratoxin A results in increased expression of DNMT1 protein Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 protein] |
CTD |
PMID:29080797 PMID:30923867 |
|
NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844
|
|
G |
DNMT3A |
DNA methyltransferase 3 alpha |
increases expression |
EXP |
ochratoxin A results in increased expression of DNMT3A mRNA |
CTD |
PMID:29080797 PMID:30923867 |
|
NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
decreases expression multiple interactions |
EXP |
ochratoxin A results in decreased expression of GCLC mRNA ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GCLC mRNA] |
CTD |
PMID:18547363 |
|
NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530
|
|
G |
GLMN |
glomulin, FKBP associated protein |
increases expression |
EXP |
ochratoxin A results in increased expression of GLMN mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 4:124,773,957...124,813,336
Ensembl chr 4:124,773,980...124,813,335
|
|
G |
GPX1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
EXP |
ochratoxin A results in decreased expression of GPX1 mRNA Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GPX4 |
glutathione peroxidase 4 |
decreases expression multiple interactions |
EXP |
ochratoxin A results in decreased expression of GPX4 mRNA Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931
|
|
G |
GSDMD |
gasdermin D |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein] |
CTD |
PMID:36281498 |
|
NCBI chr 4:995,753...1,001,964
Ensembl chr 4:995,763...1,000,271
|
|
G |
H2AX |
H2A.X variant histone |
multiple interactions increases expression |
EXP |
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein] |
CTD |
PMID:30923867 PMID:32454083 |
|
NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084
|
|
G |
HAVCR1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of HAVCR1 mRNA |
CTD |
PMID:33905761 |
|
NCBI chr16:66,162,318...66,208,868
|
|
G |
HDAC1 |
histone deacetylase 1 |
multiple interactions increases expression |
EXP |
Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 mRNA]; Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 protein] ochratoxin A results in increased expression of HDAC1 mRNA; ochratoxin A results in increased expression of HDAC1 protein |
CTD |
PMID:29080797 |
|
NCBI chr 6:88,749,611...88,785,220
Ensembl chr 6:88,749,634...88,785,411
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
increases expression decreases expression |
EXP |
ochratoxin A results in increased expression of HSP90B1 mRNA ochratoxin A results in decreased expression of HSP90B1 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
ochratoxin A results in increased expression of HSPA5 mRNA; ochratoxin A results in increased expression of HSPA5 protein |
CTD |
PMID:28699257 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
HSPD1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of HSPD1 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr15:101,360,355...101,373,498
Ensembl chr15:101,360,094...101,373,526
|
|
G |
ID2 |
inhibitor of DNA binding 2 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of ID2 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 3:127,500,759...127,503,207
Ensembl chr 3:127,500,763...127,503,257
|
|
G |
IGFBP2 |
insulin like growth factor binding protein 2 |
increases expression |
EXP |
ochratoxin A results in increased expression of IGFBP2 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr15:118,822,092...118,850,985
Ensembl chr15:118,822,047...118,850,976
|
|
G |
IL18 |
interleukin 18 |
increases expression |
EXP |
ochratoxin A results in increased expression of IL18 protein |
CTD |
PMID:36281498 |
|
NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions |
EXP |
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]] |
CTD |
PMID:28528741 |
|
NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,121
|
|
G |
IL2 |
interleukin 2 |
decreases secretion |
EXP |
ochratoxin A results in decreased secretion of IL2 protein |
CTD |
PMID:28699257 |
|
NCBI chr 8:101,640,938...101,645,683
Ensembl chr 8:101,640,944...101,645,609
|
|
G |
IL4 |
interleukin 4 |
increases expression |
EXP |
ochratoxin A results in increased expression of IL4 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365
|
|
G |
IL6 |
interleukin 6 |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of IL6 mRNA NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA] |
CTD |
PMID:28710020 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
JAK2 |
Janus kinase 2 |
multiple interactions increases phosphorylation |
EXP |
Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of JAK2 protein] |
CTD |
PMID:30923867 |
|
NCBI chr 1:216,849,744...217,002,310
Ensembl chr 1:216,848,689...217,002,148
|
|
G |
LCN2 |
lipocalin 2 |
multiple interactions |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of LCN2 mRNA |
CTD |
PMID:33905761 |
|
NCBI chr 1:268,609,975...268,614,651
Ensembl chr 1:268,609,887...268,614,644
|
|
G |
LOC106504562 |
glutathione S-transferase alpha M14 |
multiple interactions decreases expression |
EXP |
ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GSTA1 mRNA] ochratoxin A results in decreased expression of GSTA1 mRNA |
CTD |
PMID:18547363 |
|
NCBI chr 7:46,553,813...46,567,596
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein] |
CTD |
PMID:36281498 |
|
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
ochratoxin A results in increased phosphorylation of MAPK1 protein ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:28528741 PMID:28699257 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] ochratoxin A results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:28528741 PMID:28699257 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
EXP |
ochratoxin A results in decreased phosphorylation of MTOR protein |
CTD |
PMID:30287338 |
|
NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
multiple interactions |
EXP |
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 protein] |
CTD |
PMID:28528741 |
|
NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109
|
|
G |
MYG1 |
MYG1 exonuclease |
decreases expression |
EXP |
ochratoxin A results in decreased expression of PFDN5 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 5:18,512,637...18,516,928
Ensembl chr 5:18,512,697...18,517,174
|
|
G |
NEIL1 |
nei like DNA glycosylase 1 |
decreases expression multiple interactions |
EXP |
ochratoxin A results in decreased expression of NEIL1 mRNA alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA] |
CTD |
PMID:30923867 |
|
NCBI chr 7:58,261,761...58,269,001
Ensembl chr 7:58,261,769...58,268,522
|
|
G |
NEIL3 |
nei like DNA glycosylase 3 |
multiple interactions decreases expression |
EXP |
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA] |
CTD |
PMID:30923867 |
|
NCBI chr15:39,416,073...39,632,313
Ensembl chr15:39,581,856...39,632,308
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
decreases activity multiple interactions decreases expression |
EXP |
ochratoxin A results in decreased activity of NFE2L2 protein NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TP53 protein]; ochratoxin A inhibits the reaction [sulforaphane affects the localization of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased expression of NFE2L2 mRNA] ochratoxin A results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:18547363 PMID:18547704 PMID:28710020 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein] |
CTD |
PMID:36281498 |
|
NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228
|
|
G |
NOS2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of INOS mRNA Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of INOS mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of INOS mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146
|
|
G |
NPM1 |
nucleophosmin 1 |
increases expression |
EXP |
ochratoxin A results in increased expression of NPM1 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr16:52,767,263...52,781,862
Ensembl chr16:52,765,298...52,781,771
|
|
G |
NTN1 |
netrin 1 |
multiple interactions increases expression |
EXP |
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of NTN1 mRNA] |
CTD |
PMID:33905761 |
|
NCBI chr12:54,089,444...54,292,191
Ensembl chr12:54,089,472...54,292,193
|
|
G |
OGG1 |
8-oxoguanine DNA glycosylase |
decreases expression multiple interactions |
EXP |
ochratoxin A results in decreased expression of OGG1 mRNA alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA] |
CTD |
PMID:30923867 |
|
NCBI chr13:66,038,669...66,045,478
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
increases cleavage increases expression multiple interactions |
EXP |
ochratoxin A results in increased cleavage of PARP1 protein ochratoxin A results in increased expression of PARP1 protein 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein] |
CTD |
PMID:30287338 PMID:32454083 |
|
NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,160...14,241,196
|
|
G |
PCK1 |
phosphoenolpyruvate carboxykinase 1 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of PCK1 mRNA; ochratoxin A results in decreased expression of PCK1 protein |
CTD |
PMID:3753873 |
|
NCBI chr17:57,930,507...57,936,523
Ensembl chr17:57,930,432...57,936,522
|
|
G |
PCNA |
proliferating cell nuclear antigen |
decreases expression |
EXP |
ochratoxin A results in decreased expression of PCNA protein |
CTD |
PMID:32454083 |
|
NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,136,886...14,142,744
|
|
G |
PPIA |
peptidylprolyl isomerase A |
increases expression |
EXP |
ochratoxin A results in increased expression of PPIA mRNA |
CTD |
PMID:14994279 |
|
NCBI chr18:50,563,130...50,566,857
|
|
G |
PRDX1 |
peroxiredoxin 1 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of PRDX1 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 6:165,847,390...165,859,918
Ensembl chr 6:165,824,395...165,861,442
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PTGS2 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of PTGS2 mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
PTMA |
prothymosin alpha |
decreases expression |
EXP |
ochratoxin A results in decreased expression of PTMA mRNA |
CTD |
PMID:14994279 |
|
NCBI chr15:132,353,763...132,361,442
Ensembl chr15:132,355,655...132,361,435
|
|
G |
PYCARD |
PYD and CARD domain containing |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of PYCARD protein Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein] |
CTD |
PMID:36281498 |
|
NCBI chr 3:17,305,921...17,307,521
Ensembl chr 3:17,306,099...17,307,786
|
|
G |
RAD51 |
RAD51 recombinase |
increases expression |
EXP |
ochratoxin A results in increased expression of RAD51 protein |
CTD |
PMID:32454083 |
|
NCBI chr 1:130,592,414...130,640,326
Ensembl chr 1:130,586,665...130,640,136
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] |
CTD |
PMID:28528741 |
|
NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469
|
|
G |
RPA2 |
replication protein A2 |
increases expression |
EXP |
ochratoxin A results in increased expression of RPA2 protein |
CTD |
PMID:32454083 |
|
NCBI chr 6:85,032,604...85,045,899
Ensembl chr 6:85,031,582...85,045,915
|
|
G |
RPS5 |
ribosomal protein S5 |
increases expression |
EXP |
ochratoxin A results in increased expression of RPS5 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 6:62,967,955...62,974,353
Ensembl chr 6:62,967,994...62,974,350
|
|
G |
SOCS3 |
suppressor of cytokine signaling 3 |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of SOCS3 mRNA; ochratoxin A results in increased expression of SOCS3 protein Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 mRNA]; Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 protein] |
CTD |
PMID:30923867 |
|
NCBI chr12:3,643,832...3,647,015
Ensembl chr12:3,643,929...3,647,009
|
|
G |
SOD1 |
superoxide dismutase 1 |
decreases activity |
EXP |
ochratoxin A results in decreased activity of SOD1 protein |
CTD |
PMID:18547704 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
multiple interactions increases expression |
EXP |
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of SPP1 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of SPP1 mRNA] |
CTD |
PMID:33905761 |
|
NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions decreases expression |
EXP |
Chloroquine inhibits the reaction [ochratoxin A results in decreased expression of SQSTM1 protein] |
CTD |
PMID:30287338 |
|
NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions increases phosphorylation |
EXP |
Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of STAT3 protein]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein] |
CTD |
PMID:30923867 |
|
NCBI chr12:20,407,316...20,471,091
Ensembl chr12:20,407,233...20,472,992
|
|
G |
SUMO1 |
small ubiquitin like modifier 1 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of SUMO1 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr15:105,820,237...105,850,099
Ensembl chr15:105,818,858...105,850,233
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of TGFB1 mRNA NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; sulforaphane inhibits the reaction [ochratoxin A results in increased expression of TGFB1 mRNA] |
CTD |
PMID:28710020 |
|
NCBI chr 6:49,332,169...49,348,642
Ensembl chr 6:49,332,173...49,349,046
|
|
G |
TIMP2 |
TIMP metallopeptidase inhibitor 2 |
increases expression |
EXP |
ochratoxin A results in increased expression of TIMP2 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr12:3,254,794...3,300,835
Ensembl chr12:3,254,493...3,300,834
|
|
G |
TJP1 |
tight junction protein 1 |
affects localization |
EXP |
ochratoxin A affects the localization of TJP1 protein |
CTD |
PMID:14994279 |
|
NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
EXP |
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] |
CTD |
PMID:28528741 |
|
NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,058,970
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases secretion |
EXP |
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] ochratoxin A results in increased secretion of TNF protein |
CTD |
PMID:28528741 PMID:28699257 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,415
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions increases expression |
EXP |
NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TP53 protein] |
CTD |
PMID:28710020 PMID:32454083 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|
G |
XPA |
XPA, DNA damage recognition and repair factor |
decreases expression |
EXP |
ochratoxin A results in decreased expression of XPA mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 1:239,532,331...239,568,589
Ensembl chr 1:239,532,272...239,568,570
|
|
G |
XRCC1 |
X-ray repair cross complementing 1 |
increases expression |
EXP |
ochratoxin A results in increased expression of XRCC1 protein |
CTD |
PMID:32454083 |
|
NCBI chr 6:50,403,691...50,425,730
Ensembl chr 6:50,403,689...50,425,729
|
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
decreases activity |
EXP |
ochratoxin B results in decreased activity of NFE2L2 protein |
CTD |
PMID:18547704 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
|
G |
PNLIP |
pancreatic lipase |
decreases activity |
EXP |
Orlistat results in decreased activity of PNLIP protein |
CTD |
PMID:21438711 |
|
NCBI chr14:126,771,920...126,789,097
Ensembl chr14:126,772,911...126,790,001
|
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of CXCL8 protein |
CTD |
PMID:15912099 |
|
NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions increases expression |
EXP |
Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EDN1 protein] |
CTD |
PMID:17105827 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation |
EXP |
Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:11325585 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases phosphorylation |
EXP |
Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:11325585 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
EXP |
Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:11325585 |
|
NCBI chr 2:78,338,466...78,399,108
Ensembl chr 2:78,338,376...78,399,100
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
decreases expression multiple interactions |
EXP |
Tetradecanoylphorbol Acetate results in decreased expression of PPARA; Tetradecanoylphorbol Acetate results in decreased expression of PPARA protein calphostin C promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of PPARA]; Tetradecanoylphorbol Acetate inhibits the reaction [Clofibrate results in increased expression of PPARA] |
CTD |
PMID:17105827 PMID:20568414 |
|
NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239
|
|
G |
PRKCB |
protein kinase C beta |
decreases phosphorylation |
EXP |
Tetradecanoylphorbol Acetate results in decreased phosphorylation of PRKCB protein |
CTD |
PMID:15089098 |
|
NCBI chr 3:21,995,227...22,383,628
Ensembl chr 3:21,995,231...22,383,264
|
|
G |
PRKCD |
protein kinase C delta |
increases phosphorylation |
EXP |
Tetradecanoylphorbol Acetate results in increased phosphorylation of PRKCD protein |
CTD |
PMID:15089098 |
|
NCBI chr13:35,290,835...35,323,245
Ensembl chr13:35,290,610...35,323,356
|
|
G |
SELE |
selectin E |
increases expression |
EXP |
Tetradecanoylphorbol Acetate results in increased expression of SELE protein |
CTD |
PMID:16797888 |
|
NCBI chr 4:81,289,061...81,299,657
|
|
G |
SELP |
selectin P |
increases expression |
EXP |
Tetradecanoylphorbol Acetate results in increased expression of SELP protein |
CTD |
PMID:16797888 |
|
NCBI chr 4:81,376,804...81,401,240
Ensembl chr 4:81,365,740...81,399,955
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
increases expression |
EXP |
Tetradecanoylphorbol Acetate results in increased expression of VCAM1 protein |
CTD |
PMID:16797888 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
increases export multiple interactions |
EXP |
ABCB4 protein results in increased export of Phosphatidylcholines Itraconazole inhibits the reaction [ABCB4 protein results in increased export of Phosphatidylcholines]; Verapamil inhibits the reaction [ABCB4 protein results in increased export of Phosphatidylcholines] |
CTD |
PMID:21056966 |
|
NCBI chr 9:93,171,371...93,262,124
|
|
G |
PDIA3 |
protein disulfide isomerase family A member 3 |
increases hydrolysis |
EXP |
PDIA3 protein results in increased hydrolysis of Phosphatidylcholines |
CTD |
PMID:16798117 |
|
NCBI chr 1:127,786,174...127,814,096
Ensembl chr 1:127,785,772...127,814,196
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions decreases expression |
EXP |
Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 mRNA]; Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 protein]; Ritonavir results in decreased expression of and results in decreased activity of NOS3 protein Ritonavir results in decreased expression of NOS3 mRNA; Ritonavir results in decreased expression of NOS3 protein |
CTD |
PMID:15681703 PMID:16123675 PMID:22037733 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
decreases expression |
EXP |
Saquinavir results in decreased expression of NOS3 mRNA |
CTD |
PMID:16123675 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
COMT |
catechol-O-methyltransferase |
decreases activity |
EXP |
sinefungin results in decreased activity of COMT protein |
CTD |
PMID:26577531 |
|
NCBI chr14:51,384,729...51,403,997
Ensembl chr14:51,385,738...51,403,998
|
|
|
G |
PLA2G1B |
phospholipase A2 group IB |
multiple interactions |
EXP |
Sulindac promotes the reaction [PLA2G1B protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:10706128 |
|
NCBI chr14:40,314,520...40,322,315
Ensembl chr14:40,314,520...40,322,315
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Sulindac promotes the reaction [PLA2G1B protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:10706128 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
|
G |
ATF4 |
activating transcription factor 4 |
increases expression |
EXP |
T-2 Toxin results in increased expression of ATF4 protein |
CTD |
PMID:34637808 |
|
NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368
|
|
G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
multiple interactions increases expression |
EXP |
2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [evodiamine inhibits the reaction [T-2 Toxin results in increased expression of CASP1 protein]]; evodiamine inhibits the reaction [T-2 Toxin results in increased expression of CASP1 mRNA]; evodiamine inhibits the reaction [T-2 Toxin results in increased expression of CASP1 protein] T-2 Toxin results in increased expression of CASP1 mRNA; T-2 Toxin results in increased expression of CASP1 protein |
CTD |
PMID:39305878 |
|
NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases expression |
EXP |
4-phenylbutyric acid inhibits the reaction [T-2 Toxin results in increased expression of CASP3 protein modified form]; 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine inhibits the reaction [T-2 Toxin results in increased expression of CASP3 protein modified form] |
CTD |
PMID:34637808 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CAT |
catalase |
multiple interactions decreases activity |
EXP |
evodiamine inhibits the reaction [T-2 Toxin results in decreased activity of CAT protein] |
CTD |
PMID:39305878 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CHUK |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression multiple interactions |
EXP |
T-2 Toxin results in increased expression of CHUK protein evodiamine inhibits the reaction [T-2 Toxin results in increased expression of CHUK protein] |
CTD |
PMID:39305878 |
|
NCBI chr14:111,316,178...111,351,669
Ensembl chr14:111,315,141...111,351,868
|
|
G |
CLDN1 |
claudin 1 |
decreases expression multiple interactions |
EXP |
T-2 Toxin results in decreased expression of CLDN1 mRNA; T-2 Toxin results in decreased expression of CLDN1 protein 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of CLDN1 protein]]; evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of CLDN1 mRNA]; evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of CLDN1 protein] |
CTD |
PMID:39305878 |
|
NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
EXP |
T-2 Toxin results in increased expression of DDIT3 protein |
CTD |
PMID:34637808 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation |
EXP |
T-2 Toxin results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:34637808 |
|
NCBI chr 3:57,423,894...57,506,247
Ensembl chr 3:57,423,943...57,506,245
|
|
G |
EIF2S1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
EXP |
T-2 Toxin results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:34637808 |
|
NCBI chr 7:91,085,025...91,109,835
Ensembl chr 7:91,085,335...91,109,827
|
|
G |
GSDMD |
gasdermin D |
increases expression multiple interactions |
EXP |
T-2 Toxin results in increased expression of GSDMD protein 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [evodiamine inhibits the reaction [T-2 Toxin results in increased expression of GSDMD protein]]; evodiamine inhibits the reaction [T-2 Toxin results in increased expression of GSDMD protein] |
CTD |
PMID:39305878 |
|
NCBI chr 4:995,753...1,001,964
Ensembl chr 4:995,763...1,000,271
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression |
EXP |
T-2 Toxin results in decreased expression of HSPA5 protein |
CTD |
PMID:34637808 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
IL18 |
interleukin 18 |
increases expression multiple interactions |
EXP |
T-2 Toxin results in increased expression of IL18 mRNA; T-2 Toxin results in increased expression of IL18 protein evodiamine inhibits the reaction [T-2 Toxin results in increased expression of IL18 mRNA]; evodiamine inhibits the reaction [T-2 Toxin results in increased expression of IL18 protein] |
CTD |
PMID:39305878 |
|
NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219
|
|
G |
KEAP1 |
kelch like ECH associated protein 1 |
decreases expression multiple interactions |
EXP |
T-2 Toxin results in decreased expression of KEAP1 protein 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of KEAP1 protein]]; evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of KEAP1 protein] |
CTD |
PMID:39305878 |
|
NCBI chr 2:69,280,940...69,290,267
Ensembl chr 2:69,276,336...69,294,382
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
multiple interactions increases expression |
EXP |
evodiamine inhibits the reaction [T-2 Toxin results in increased expression of IL1B mRNA]; evodiamine inhibits the reaction [T-2 Toxin results in increased expression of IL1B protein] T-2 Toxin results in increased expression of IL1B mRNA; T-2 Toxin results in increased expression of IL1B protein |
CTD |
PMID:39305878 |
|
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
affects localization decreases expression multiple interactions |
EXP |
T-2 Toxin affects the localization of NFE2L2 protein T-2 Toxin results in decreased expression of NFE2L2 mRNA 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide affects the reaction [evodiamine affects the reaction [T-2 Toxin affects the localization of NFE2L2 protein]]; evodiamine affects the reaction [T-2 Toxin affects the localization of NFE2L2 protein]; evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:39305878 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions increases expression |
EXP |
2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [evodiamine inhibits the reaction [T-2 Toxin results in increased expression of NLRP3 protein]]; evodiamine inhibits the reaction [T-2 Toxin results in increased expression of NLRP3 mRNA]; evodiamine inhibits the reaction [T-2 Toxin results in increased expression of NLRP3 protein] T-2 Toxin results in increased expression of NLRP3 mRNA; T-2 Toxin results in increased expression of NLRP3 protein |
CTD |
PMID:39305878 |
|
NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228
|
|
G |
OCLN |
occludin |
multiple interactions decreases expression |
EXP |
2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of OCLN protein]]; evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of OCLN mRNA]; evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of OCLN protein] T-2 Toxin results in decreased expression of OCLN mRNA; T-2 Toxin results in decreased expression of OCLN protein |
CTD |
PMID:39305878 |
|
NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
|
|
G |
PYCARD |
PYD and CARD domain containing |
increases expression multiple interactions |
EXP |
T-2 Toxin results in increased expression of PYCARD mRNA; T-2 Toxin results in increased expression of PYCARD protein evodiamine inhibits the reaction [T-2 Toxin results in increased expression of PYCARD mRNA]; evodiamine inhibits the reaction [T-2 Toxin results in increased expression of PYCARD protein] |
CTD |
PMID:39305878 |
|
NCBI chr 3:17,305,921...17,307,521
Ensembl chr 3:17,306,099...17,307,786
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
affects localization multiple interactions increases phosphorylation increases expression |
EXP |
T-2 Toxin affects the localization of RELA protein 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide affects the reaction [evodiamine affects the reaction [T-2 Toxin affects the localization of RELA protein]]; 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [evodiamine inhibits the reaction [T-2 Toxin results in increased phosphorylation of RELA protein]]; evodiamine affects the reaction [T-2 Toxin affects the localization of RELA protein]; evodiamine inhibits the reaction [T-2 Toxin results in increased expression of RELA mRNA]; evodiamine inhibits the reaction [T-2 Toxin results in increased phosphorylation of RELA protein] |
CTD |
PMID:39305878 |
|
NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469
|
|
G |
TJP1 |
tight junction protein 1 |
decreases expression multiple interactions |
EXP |
T-2 Toxin results in decreased expression of TJP1 mRNA; T-2 Toxin results in decreased expression of TJP1 protein 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of TJP1 protein]]; evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of TJP1 mRNA]; evodiamine inhibits the reaction [T-2 Toxin results in decreased expression of TJP1 protein] |
CTD |
PMID:39305878 |
|
NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
|
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases secretion |
EXP |
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [ADIPOQ protein results in increased secretion of Testosterone]; bisphenol A inhibits the reaction [ADIPOQ protein results in increased secretion of Testosterone]; halowax 1051 promotes the reaction [ADIPOQ protein results in increased secretion of Testosterone]; Testosterone results in decreased expression of and results in decreased secretion of ADIPOQ protein |
CTD |
PMID:28284726 |
|
NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,685...124,646,646
|
|
G |
ADIPOR1 |
adiponectin receptor 1 |
decreases expression |
EXP |
Testosterone results in decreased expression of ADIPOR1 protein |
CTD |
PMID:28284726 |
|
NCBI chr10:24,907,491...24,923,540
Ensembl chr10:24,907,491...24,915,686
|
|
G |
ADIPOR2 |
adiponectin receptor 2 |
decreases expression |
EXP |
Testosterone results in decreased expression of ADIPOR2 protein |
CTD |
PMID:28284726 |
|
NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
multiple interactions |
EXP |
[2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Testosterone] affects the activity of CYP19A1 protein; [3,4,5,3',4'-pentachlorobiphenyl co-treated with Testosterone] results in increased activity of CYP19A1 protein |
CTD |
PMID:16151981 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
G |
CYP3A29 |
cytochrome P450 family 3 subfamily A member 29 |
multiple interactions increases hydroxylation |
EXP |
Ketoconazole inhibits the reaction [CYP3A29 protein results in increased hydroxylation of Testosterone]; Troleandomycin inhibits the reaction [CYP3A29 protein results in increased hydroxylation of Testosterone] |
CTD |
PMID:20863320 |
|
NCBI chr 3:6,738,502...6,778,121
Ensembl chr 3:6,738,486...6,778,944
|
|
G |
INS |
insulin |
multiple interactions |
EXP |
9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone]; [LHB protein co-treated with INS protein] results in increased abundance of Testosterone; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone] |
CTD |
PMID:11889176 |
|
NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
|
|
G |
LHB |
luteinizing hormone subunit beta |
increases secretion multiple interactions |
EXP |
LHB protein results in increased secretion of Testosterone 9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone]; [LHB protein co-treated with INS protein] results in increased abundance of Testosterone; Biological Products inhibits the reaction [LHB protein results in increased secretion of Testosterone]; Cod Liver Oil inhibits the reaction [LHB protein results in increased secretion of Testosterone]; Industrial Waste inhibits the reaction [LHB protein results in increased secretion of Testosterone]; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone] |
CTD |
PMID:11889176 PMID:26055946 |
|
NCBI chr 6:54,263,574...54,269,286
Ensembl chr 6:54,263,576...54,271,086
|
|
|
G |
CYP3A29 |
cytochrome P450 family 3 subfamily A member 29 |
multiple interactions |
EXP |
Troleandomycin inhibits the reaction [CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Troleandomycin inhibits the reaction [CYP3A29 protein results in increased hydroxylation of Testosterone]; Troleandomycin inhibits the reaction [CYP3A29 protein results in increased oxidation of Nifedipine] |
CTD |
PMID:20863320 |
|
NCBI chr 3:6,738,502...6,778,121
Ensembl chr 3:6,738,486...6,778,944
|
|
|
G |
GH1 |
growth hormone 1 |
multiple interactions |
EXP |
GH1 protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Urea] |
CTD |
PMID:9185964 |
|
NCBI chr12:15,064,965...15,066,698
Ensembl chr12:15,064,909...15,066,696
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Wortmannin inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16239170 |
|
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
Wortmannin inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; Wortmannin inhibits the reaction [TNF protein results in increased expression of HIF1A protein] |
CTD |
PMID:11514583 |
|
NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
Wortmannin inhibits the reaction [sodium arsenite results in increased phosphorylation of NOS3 protein] |
CTD |
PMID:16239170 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
G |
RPS6 |
ribosomal protein S6 |
decreases phosphorylation multiple interactions |
EXP |
Wortmannin results in decreased phosphorylation of RPS6 protein Wortmannin promotes the reaction [Ivermectin results in decreased phosphorylation of RPS6 protein] |
CTD |
PMID:31400776 |
|
NCBI chr 1:203,444,360...203,447,643
Ensembl chr 1:203,444,450...203,451,468
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
Wortmannin inhibits the reaction [TNF protein results in increased expression of HIF1A protein] |
CTD |
PMID:11514583 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,415
|
|
|
G |
ALOX5 |
arachidonate 5-lipoxygenase |
decreases activity |
EXP |
zileuton results in decreased activity of ALOX5 protein |
CTD |
PMID:11509739 |
|
NCBI chr14:90,859,209...90,907,084
Ensembl chr14:90,859,019...90,907,090
|
|